Advanced delivery of biologics

A Leader in Formulation Technology Innovation Find out more
  • A Leader in Formulation Technology Innovation technology/

About Arecor

A UK-based leading formulation technology company delivering superior biopharmaceuticals via the innovative reformulation of proteins and peptides

Find out more


  • By applying science of the highest calibre Arecor uncovers new insights in protein chemistry, enabling development of differentiating next generation biologics.

    Alan Smith, FRS CBE, Former CSO, Genzyme

  • The Arecor technology has a demonstrated potential to significantly improve the stability of complex biologicals by using novel formulation design principles.

    Bob Mattaliano, Group VP Biologics Development, Genzyme

  • Arecor’s biologic stabilisation technology provided the stabilisation breakthrough needed for commercialisation of Oxyzyme and Iodozyme, Archimed's unique wound healing products.

    Paul Davis, Chief Scientific Officer, Archimed LLP

  • We are very pleased with the work Arecor has done with our lead vaccine candidate REDEE FLU™. Providing a more effective influenza vaccine that maintains its stability is our ultimate goal at FluGen and we are indebted to the UK government and Arecor for making this possible.

    Paul Radspinner, Chief Executive Officer, Flugen

  • Arecor has transformed the development paths and delivery options for a wide range of new therapeutic products by working closely with partner companies to employ their suite of rationally-derived stabilisation technologies.

    Andy J M Richards, Biotechnology Entrepreneur and Business Angel